7 citations
,
June 1967 in “Journal of Investigative Dermatology”
This study reports an unusual finding of plucked anagen hairs with intact hair papilla and connectivetissuesheath in various scalp disorders, suggesting further documentation is needed.
This study combined spatial and single-cell transcriptomics to identify that hypercontractility of the connectivetissuesheath activates PIEZO1 in hair follicles, leading to miniaturization in male androgenetic alopecia, and found that inhibiting this contraction improves hair growth in models.
December 2023 in “bioRxiv (Cold Spring Harbor Laboratory)”
This study found that targeting connectivetissuesheath contraction with an MLCK inhibitor may improve hair growth in androgenetic alopecia by reducing premature hair regression caused by ectopic apoptosis of hair follicle progenitor cells.
The conversation discusses taurine supplements for hair growth, highlighting their potential to reduce DHT and improve hair health. A user comments that people often try alternatives to finasteride.
GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.
Clascoterone (Breezula) shows promising hair growth results, but skepticism remains due to past disappointments with new treatments. It may be a good alternative for those who can't tolerate finasteride or dutasteride, and can potentially be combined with them and minoxidil for better results.
Procapil is marketed as a natural hair loss treatment but lacks strong evidence and is industry-biased. Minoxidil and Finasteride are the only FDA-approved treatments for androgenetic alopecia.